The CHAMP clinical trial and NVK002 for controlling paediatric myopia
Ophthalmology Times Europe,
Thus far, the drug’s efficacy has been maintained out to 3 years, but additional studies are needed.
Thus far, the drug’s efficacy has been maintained out to 3 years, but additional studies are needed.
Click to save this article.You'll be asked to sign into your Forbes account.Got itJan 7, 2024,01:17pm EST This story is part of…
The FDA’s advisory committees of outside experts typically review controversial drug approval decisions at meetings scheduled…
(Image Credit: AdobeStock/Kenishirotie) Vyluma Inc announced positive top-line results from the second stage of its Phase III…